Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vacci... Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. Mehr anzeigen
Merck Underscores Continued Commitment to Fighting Infectious Diseases with More than 40 Data Presentations Across Vaccines, Antibacterials and Antivirals, Including Respiratory Syncytial Virus...
KEYNOTE-689 is the first Phase 3 trial to demonstrate statistically significant and clinically meaningful improvement in EFS in the intent-to-treat population in the neoadjuvant and adjuvant...
October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring...
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More PR Newswire NEW YORK, Oct. 3, 2024 NetworkNewsWire Editorial Coverage NEW YORK, Oct. 3, 2024 /PRNewswire/...
Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline Merck (NYSE:...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m...
Tulisokibart is now being evaluated in two Phase 3 studies in ulcerative colitis and Crohn’s disease 12-week data from the Phase 2 ARTEMIS-UC trial recently published in the New England Journal...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.35 | -0.318616294948 | 109.85 | 110.98 | 107.81 | 8358382 | 109.31201525 | CS |
| 4 | -6.05 | -5.23582864561 | 115.55 | 119.38 | 107.81 | 9622569 | 113.95239943 | CS |
| 12 | -15.8 | -12.6097366321 | 125.3 | 128.73 | 107.81 | 9643339 | 115.48963634 | CS |
| 26 | -17.05 | -13.4729355986 | 126.55 | 134.63 | 107.81 | 8546320 | 121.62527608 | CS |
| 52 | 5.51 | 5.29858640254 | 103.99 | 134.63 | 99.14 | 8470592 | 118.26646151 | CS |
| 156 | 27.865 | 34.1336436577 | 81.635 | 134.63 | 71.5 | 9333750 | 100.9324824 | CS |
| 260 | 25.135 | 29.7931606709 | 84.365 | 134.63 | 65.25 | 9917716 | 91.47090084 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
